Sutter Biobank Targets Alzheimer’s Look-Alikes | Mirage News

SACRAMENTO, Calif., Nov. 16, 2026– Sutter Health scientists have actually introduced a biobank computer system registry to speed up research study into LATE, a lesser-known kind of dementia that can imitate Alzheimer’s illness however comes from a various underlying cause.

The LATE Biobank Registry permits Sutter scientists to study biological samples and medical information from clients who fulfill scientific requirements for LATE. By gathering samples throughout clients’ care, scientists wish to much better comprehend the illness, establish and confirm biomarkers and prepared for future scientific trials.

“The LATE registry demonstrates the broader promise of the Sutter Biobank: connecting biological samples with rich clinical information from patients receiving care across our system. By building research resources around diseases of aging, we can investigate why people experience conditions such as dementia differently and accelerate the search for biomarkers and more personalized approaches to prevention, diagnosis and treatment,” stated Greg Tranah, Ph.D., senior researcher and director of the Sutter Biobank.

Dr. Shawn Kile chair of Sutter Health’s Advanced Neuroscience Service Line will provide early findings from the pc registry Nov. 18 at the Clinical Trials on Alzheimer’s Disease conference in Boston. His abstract discussion, “Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health,” information the development of the windows registry and its preliminary registration.

LATE, or limbic-predominant age-related TDP-43 encephalopathy, is connected with an irregular accumulation of the protein TDP-43 in locations of the brain important to memory. Unlike Alzheimer’s illness, LATE presently has no particular biomarkers or understood treatments.

“Based on autopsy studies, we are learning that LATE pathology is showing up in approximately 40% of people age 80 and older. This is significant. Whether this is the primary driver of cognitive decline in some cases or co-pathology in other cases, it is important to understand,” stated Dr. Kile. “By collecting blood and cerebrospinal fluid from clinically suspected cases over time, this biobank registry can help us close current knowledge gaps and, ultimately, move toward a biomarker-driven diagnosis and more precise treatments for LATE.”

The Alzheimer’s Association launched in 2025 scientific requirements for LATE. As biomarker screening makes it simpler to recognize Alzheimer’s, scientists are likewise acknowledging clients whose amnesia looks like Alzheimer’s, however who evaluate unfavorable for amyloid and tau biomarkers connected with the illness. “Some of these patients may instead have LATE,” states Dr. Kile.

Sutter’s LATE Biobank Registry opened for registration in May 2026. At the time of abstract submission, scientists had actually determined 21 clients who satisfied eligibility requirements, with 6 granted get involved. Qualified clients can register through getting involved Sutter Health affiliates throughout California. As the computer registry grows, it likewise produces an accomplice of clients for future scientific trials of treatments targeting TDP-43.

“A health system like Sutter can leverage their patients to advance dementia research, from identifying patients in clinical care and collecting samples over time to studying new biomarkers and preparing for future trials. That connection between research and real-world care gives us an important opportunity to improve how neurodegenerative diseases such as LATE are recognized and, ultimately, treated,” Stated Armen Moughamian, M.D., Ph.D., chief of memory for Sutter’s Neuroscience Service Line and medical director of Sutter’s Ray Dolby Brain Health Center at California Pacific Medical.

More on Dr. Shawn Kile

Shawn Kile, M.D., is a board-certified neurologist focusing on cognitive conditions and chair of Sutter Health’s Advanced Neuroscience Service Line. He assisted develop Sutter’s Advanced Therapeutics for Alzheimer’s Disease Review Board and acts as a primary private investigator for research studies assessing emerging treatments for Alzheimer’s illness and other neurocognitive conditions. His work integrates client care, medical research study and development concentrated on enhancing the medical diagnosis and treatment of dementia.

About Sutter Health

Sutter Health is a not-for-profit health care system devoted to supplying detailed care throughout California. Directed by a dedication to advancing ingenious client care, healthy results and neighborhood collaborations, Sutter is pursuing a vibrant strategy to reach more individuals and make outstanding health care more linked, available and tailored.

Today, its devoted group of more than 64,000 staff members and clinicians and 15,000+ connected doctors take care of more than 3.6 million clients and are unified by a shared concentrate on broadening care to serve more clients. Sutter provides remarkable and budget-friendly care through its health centers, medical groups, ambulatory surgical treatment centers, immediate care centers, telehealth, home health and hospice services.

/ Public Release. This product from the stemming organization/author(s) may be of the point-in-time nature, and modified for clearness, design and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions revealed herein are entirely those of the author(s). View completely here.


Discover more from PMN S.P.O.R.T.S - A PRIME MEDIA NETWORK BRAND

Subscribe to get the latest posts sent to your email.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Captcha verification failed!
CAPTCHA user score failed. Please contact us!

spot_imgspot_imgspot_imgspot_img